The IMmunotherapy Pleural 5-ALA PDT

Inclusion Criteria: * ECOG Performance status (PS) 0-1 (WHO) * Unresectable Malignant Pleural Mesothelioma * suffering from unresectable MPM (n=20), relapsing after one or 2 lines of treatment with platinum-based doublet of chemotherapy (including pemetrexed) \[Note: MPM patients having contra-indications for, or refusing chemotherapy may also be recruited\], and candidate for palliative pleural procedure (i.e. thoracoscopy for pleurodesis by talc or by insertion of indwelled pleural catheter, IPC) * Documented progression after previous 1 or 2 lines of chemotherapy including Platinum/Pemetrexed chemotherapy\* * Measurable disease according to modified RECIST 1.1. for MPM * Malignant pleural lesion assessed to be accessible by local PDT treatment during thoracoscopy, as validated by expert MTB ("MESOCLIN", Lille, France) * Histological diagnosis confirmed by national expert pathology panel ("MESOPATH" - Institut Léon Bérard, Lyon, France) * Weight loss \<10% * available tumor tissue (archival or fresh) * obtention of an informed written consent before any specific procedure of the study * Decision to treat the patient within this clinical trial taken during MPM dedicated multidisciplinary board (RCP MESOCLIN in France ) * Patient affiliated to and covered by social security for standard care * Women of child-bearing potential must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using su…